Elizabeth A Sugg from Chicago, IL, age 35

Oxoazepine Derivatives
view source
US Patent:

5889182, Mar 30, 1999
Filed:

Apr 14, 1997
Appl. No.:

8/817363
Inventors:

Milana Dezube - Chapel Hill NC
Gavin Charles Hirst - Marlboro MA
Ronald George Sherrill - Cary NC
Elizabeth Ellen Sugg - Durham NC
Jerzy Ryszard Szewczyk - Chapel Hill NC
Timothy Mark Willson - Durham NC
Assignee:

Glaxo Wellcome Inc. - Research Triangle Park NC
International Classification:

C07D22316
A61K 3153
US Classification:

540527
Abstract:

This invention relates to novel oxoazepine derivatives of Formula (I), R. sup. 1 R. sup. 2 NCOCH. sub. 2 N(R. sup. 3)COR. sup. 4 (I) to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine. More particularly, it relates to compounds which exhibit agonist activity for CCK-A receptors thereby enabling them to modulate the hormones gastrin and cholecystokinin (CCK) in mammals.

1,5-Benzodiazepine Derivatives Having Cck Antagonistic Or Agonistic Activity
view source
US Patent:

56461402, Jul 8, 1997
Filed:

Oct 13, 1995
Appl. No.:

8/525659
Inventors:

Elizabeth Ellen Sugg - Research Triangle Park NC
Christopher Joseph Aquino - Research Triangle Park NC
Jerzy Ryszard Szewczyk - Research Triangle Park NC
Harry Finch - Stevenage, GB
Robin Arthur Ellis Carr - Stevenage, GB
Assignee:

Glaxo Wellcome Inc. - Research Triangle Park NC
International Classification:

C07D24312
A61K 3155
US Classification:

517221
Abstract:

This invention pertains to novel benzodiazepine compounds of formula (I) ##STR1## which exhibit agonistic activity for CCK-A receptors, enabling them to modulate the hormones gastrin and cholecystokinin (CCK) in mammals for use in medicine as anorectic agents in the regulation of appetite, the treatment of obesity and the maintenance of weight loss.

Enteric Coated Compositions Of 1,5-Benzodiazepine Derivatives Having Cck Antagonistic Or Agonistic Activity
view source
US Patent:

57804648, Jul 14, 1998
Filed:

Apr 14, 1997
Appl. No.:

8/817364
Inventors:

Elizabeth Ellen Sugg - Durham NC
Assignee:

Glaxo Wellcome Inc. - Research Triangle Park NC
International Classification:

A61K 3155
US Classification:

514221
Abstract:

A pharmaceutical formulation in solid dosage form for oral administration which comprises a compound of the general Formula (I) ##STR1## or a physiologically acceptable salt or solvate thereof together with one or more pharmaceutically acceptable carriers wherein the formulation is encased in an enteric coating or capsule.

Modulators Of Cholecystokinin
view source
US Patent:

53808720, Jan 10, 1995
Filed:

Jul 14, 1992
Appl. No.:

7/914918
Inventors:

Elizabeth E. Sugg - Durham NC
Milana Dezube - Chapel Hill NC
Gavin C. Hirst - Carrboro NC
Assignee:

Glaxo Inc. - Research Triangle Park NC
International Classification:

C07D20920
US Classification:

548495
Abstract:

CCK modulators, e. g. agonists or antagonists, of the following formula (I): ##STR1## or a base-addtion salt thereof.

Modulators Of Cholecystokinin
view source
US Patent:

55084320, Apr 16, 1996
Filed:

Jun 8, 1994
Appl. No.:

8/255592
Inventors:

Elizabeth E. Sugg - Durham NC
Milana Dezube - Chapel Hill NC
Gavin C. Hirst - Carrboro NC
Assignee:

Glaxo Wellcome Inc. - Research Triangle Park NC
International Classification:

C07D20920
C07D40312
A61K 3141
A61K 31405
US Classification:

548506
Abstract:

CCK modulators, e. g. agonists or antagonists, of the following formula (I): ##STR1## or a base-addtion salt thereof.

Oxoazepine Derivatives
view source
US Patent:

58891820, Mar 30, 1999
Filed:

Apr 14, 1997
Appl. No.:

8/817363
Inventors:

Milana Dezube - Chapel Hill NC
Gavin Charles Hirst - Marlboro MA
Ronald George Sherrill - Cary NC
Elizabeth Ellen Sugg - Durham NC
Jerzy Ryszard Szewczyk - Chapel Hill NC
Timothy Mark Willson - Durham NC
Assignee:

Glaxo Wellcome Inc. - Research Triangle Park NC
International Classification:

C07D22316
A61K 3153
US Classification:

540527
Abstract:

This invention relates to novel oxoazepine derivatives of Formula (I), R. sup. 1 R. sup. 2 NCOCH. sub. 2 N(R. sup. 3)COR. sup. 4 (I) to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine. More particularly, it relates to compounds which exhibit agonist activity for CCK-A receptors thereby enabling them to modulate the hormones gastrin and cholecystokinin (CCK) in mammals.